Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

NCT03050307 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03050307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
April 17, 2017
Completion date
May 26, 2020
Enrollment
234 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

gastric ulcer